A Phase 1, Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Nanoparticle Vaccine, With or Without Matrix-M Adjuvant, in Healthy Subjects ≥18 to <50 Years of Age

Trial Profile

A Phase 1, Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Nanoparticle Vaccine, With or Without Matrix-M Adjuvant, in Healthy Subjects ≥18 to <50 Years of Age

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs EBOV GP vaccine (Primary) ; Matrix M
  • Indications Ebola virus infections
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Novavax
  • Most Recent Events

    • 20 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 08 Jun 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2016.
    • 21 Jul 2015 Top-line results published in Novavax media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top